President Trump's August 19, 2026, nomination of White House domestic policy aide Dr. Heidi Overton to serve as FDA commissioner follows the May resignation of Dr. Marty Makary and the tenure of acting commissioner Kyle Diamantas. Overton’s confirmation requires Senate approval, beginning with a hearing and vote in the HELP Committee chaired by Sen. Bill Cassidy. Cassidy immediately voiced strong concerns over her involvement in a recent vaccine-related executive order, describing elements as nonsensical and nearly disqualifying, while signaling that committee passage would likely demand unified Republican support. Sen. Patty Murray has stated opposition. These early partisan and procedural signals from key senators shape trader assessments of confirmation odds amid standard nomination scrutiny.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วใหม่
Sep 30, 2026
September 30
49%
October 31
50%
November 30
50%
December 31
50%
$453 ปริมาณ
September 30
$453 ปริมาณ
49%
October 31
$0 ปริมาณ
50%
November 30
$0 ปริมาณ
50%
December 31
$0 ปริมาณ
50%
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump's August 19, 2026, nomination of White House domestic policy aide Dr. Heidi Overton to serve as FDA commissioner follows the May resignation of Dr. Marty Makary and the tenure of acting commissioner Kyle Diamantas. Overton’s confirmation requires Senate approval, beginning with a hearing and vote in the HELP Committee chaired by Sen. Bill Cassidy. Cassidy immediately voiced strong concerns over her involvement in a recent vaccine-related executive order, describing elements as nonsensical and nearly disqualifying, while signaling that committee passage would likely demand unified Republican support. Sen. Patty Murray has stated opposition. These early partisan and procedural signals from key senators shape trader assessments of confirmation odds amid standard nomination scrutiny.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: Aug 20, 2026, 5:43 PM ET
ปริมาณการซื้อขาย
$453วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by October 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.President Trump's August 19, 2026, nomination of White House domestic policy aide Dr. Heidi Overton to serve as FDA commissioner follows the May resignation of Dr. Marty Makary and the tenure of acting commissioner Kyle Diamantas. Overton’s confirmation requires Senate approval, beginning with a hearing and vote in the HELP Committee chaired by Sen. Bill Cassidy. Cassidy immediately voiced strong concerns over her involvement in a recent vaccine-related executive order, describing elements as nonsensical and nearly disqualifying, while signaling that committee passage would likely demand unified Republican support. Sen. Patty Murray has stated opposition. These early partisan and procedural signals from key senators shape trader assessments of confirmation odds amid standard nomination scrutiny.
This market will resolve to “Yes” if Heidi Overton is confirmed as Commissioner of the U.S. Food and Drug Administration by September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to “No”.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
If Heidi Overton's nomination is formally withdrawn, or if the Senate rejects the nomination, this market will immediately resolve to “No”.
The Senate must confirm this nominee as Commissioner of the U.S. Food and Drug Administration for this market to resolve to "Yes". Recess appointments without Senate confirmation will not count toward a "Yes" resolution.
The primary resolution source for this market is official information from the U.S. Senate; however, a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$453วันสิ้นสุด
Jan 1, 2027ตลาดเปิดเมื่อ
Aug 20, 2026, 5:43 PM ETResolver
0x65070BE91...President Trump's August 19, 2026, nomination of White House domestic policy aide Dr. Heidi Overton to serve as FDA commissioner follows the May resignation of Dr. Marty Makary and the tenure of acting commissioner Kyle Diamantas. Overton’s confirmation requires Senate approval, beginning with a hearing and vote in the HELP Committee chaired by Sen. Bill Cassidy. Cassidy immediately voiced strong concerns over her involvement in a recent vaccine-related executive order, describing elements as nonsensical and nearly disqualifying, while signaling that committee passage would likely demand unified Republican support. Sen. Patty Murray has stated opposition. These early partisan and procedural signals from key senators shape trader assessments of confirmation odds amid standard nomination scrutiny.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย